KALA BIO, Inc.
KALANasdaq
$0.78
↓ -8.4%Jul 17 close · end-of-day
Price
1Y↓ -99.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$9.2M
Enterprise Value
$447,514.05
P/E
0.0
P/S
—
P/B
0.9
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$19.7M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-182.6%
ROIC
-1198.4%
Debt / Equity
—
Net Cash
$8.8M
Return 1Y
-99.7%
Company profile
Kala Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid.
- CEO
- Mark T. Iwicki
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 30
- Headquarters
- Massachusetts
- Website
- kalarx.com
Management & directors
- Reumuth MaryCHIEF FINANCIAL OFFICER
- Brazzell Romulus KSEE REMARKS
- Kharabi DariusCHIEF BUSINESS OFFICER
- Bazemore ToddSEE REMARKS
Roles derived from SEC Form 4 filings.
Earnings
KALA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.14↓ -99.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $6.4M | $11.2M | $3.9M | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$96.2M | -$130.2M | -$81.7M | -$39.7M | -$41.0M | -$39.2M |
| Net income | -$104.3M | -$142.6M | -$44.8M | -$42.2M | -$38.5M | -$27.0M |
| Diluted EPS | -$1.99 | -$108.32 | -$29.48 | -$17.35 | -$10.15 | -$3.31 |
| Operating cash flow | -$90.7M | -$108.2M | -$78.9M | -$27.9M | -$29.4M | -$32.0M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -1512.6% | -1158.8% | -2099.3% | — | — | — |
| Net margin | -1639.8% | -1268.7% | -1151.6% | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$9.6M | -$10.0M | -$9.5M | -$10.7M | -$11.0M | -$7.2M | -$10.2M | -$1.8M |
| Net income | -$9.6M | -$8.9M | -$8.2M | -$8.9M | -$11.2M | -$7.6M | $686,000.00 | -$1.6M |
| Diluted EPS | -$3.16 | -$1.93 | -$0.86 | -$70.49 | -$1.71 | -$1.07 | $69.96 | -$0.14 |
| Operating cash flow | -$9.2M | -$4.7M | -$4.6M | -$8.8M | -$16.6M | -$10.9M | $4.3M | -$2.9M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Apr 21, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-10-23 | Iwicki Mark T | Sale | 154,894 | $0.81 | $125,464.14 | filing |
| 2025-10-23 | Reumuth Mary· CHIEF FINANCIAL OFFICER | Sale | 967 | $0.82 | $792.94 | filing |
| 2025-10-22 | Bazemore Todd | Sale | 47,768 | $0.83 | $39,647.44 | filing |
| 2025-10-22 | Brazzell Romulus K· SEE REMARKS | Sale | 46,748 | $0.83 | $38,800.84 | filing |
| 2025-10-22 | Reumuth Mary· CHIEF FINANCIAL OFFICER | Sale | 32,230 | $0.83 | $26,750.90 | filing |
| 2025-10-22 | Kharabi Darius· CHIEF BUSINESS OFFICER | Sale | 20,806 | $0.83 | $17,268.98 | filing |
| 2025-10-01 | BAKER BROS. ADVISORS LP | Sale | 462,967 | $1.38 | $640,653.73 | filing |
| 2025-10-01 | BAKER BROS. ADVISORS LP | Sale | 50,640 | $1.38 | $70,075.63 | filing |
| 2025-09-30 | BAKER BROS. ADVISORS LP | Sale | 195,425 | $1.60 | $311,878.76 | filing |
| 2025-09-30 | BAKER BROS. ADVISORS LP | Sale | 21,376 | $1.60 | $34,113.96 | filing |
| 2025-06-24 | Iwicki Mark T | Sale | 13,227 | $4.01 | $53,040.27 | filing |
| 2025-06-24 | Brazzell Romulus K· SEE REMARKS | Sale | 5,251 | $4.01 | $21,056.51 | filing |
| 2025-06-24 | Kharabi Darius· CHIEF BUSINESS OFFICER | Sale | 4,511 | $4.01 | $18,089.11 | filing |
| 2025-06-24 | Bazemore Todd· SEE REMARKS | Sale | 4,058 | $4.01 | $16,272.58 | filing |
| 2025-06-24 | Reumuth Mary· CHIEF FINANCIAL OFFICER | Sale | 3,631 | $4.01 | $14,560.31 | filing |
| 2025-06-15 | Rosen Howard B | Award | 2,450 | $0.00 | $0.00 | filing |
| 2025-06-15 | Iwicki Mark T | Award | 2,450 | $0.00 | $0.00 | filing |
| 2025-06-15 | Farid Marjan | Award | 2,450 | $0.00 | $0.00 | filing |
| 2025-06-15 | PERRY GREGORY D | Award | 2,450 | $0.00 | $0.00 | filing |
| 2025-06-15 | Myers C. Daniel | Award | 2,450 | $0.00 | $0.00 | filing |
| 2025-06-15 | KOVEN ANDREW I | Award | 3,050 | $0.00 | $0.00 | filing |
Latest 21 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.